Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
38.076,50 +448,02 (+1,19%) EUR/USD
1,0725 -0,0008 (-0,08%) Bitcoin EUR
59.790,02 -100,23 (-0,17%) CMC Crypto 200
1.388,34 +5,77 (+0,42%)
Novozymes A/S (0Q4U.IL)
| Chiusura precedente | 391,70 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 567.766 |
| Capitalizzazione | 106,109B |
| Beta (5 anni mensile) | 0,44 |
| Rapporto PE (ttm) | 31,12 |
| EPS (ttm) | 12,32 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 10,20 (3,59%) |
| Data ex dividendo | 11 ott 2023 |
| Stima target 1A | 411,63 |
GlobeNewswireNovozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
- GlobeNewswire
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
- GlobeNewswire
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing. COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the fi
